NEOGEN CORP (NEOG) Stock Fundamental Analysis

NASDAQ:NEOG • US6404911066

11.33 USD
+0.35 (+3.19%)
At close: Feb 20, 2026
11.36 USD
+0.03 (+0.26%)
After Hours: 2/20/2026, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NEOG. NEOG was compared to 185 industry peers in the Health Care Equipment & Supplies industry. The financial health of NEOG is average, but there are quite some concerns on its profitability. NEOG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • NEOG had positive earnings in the past year.
  • NEOG had a positive operating cash flow in the past year.
  • In multiple years NEOG reported negative net income over the last 5 years.
  • In the past 5 years NEOG always reported a positive cash flow from operatings.
NEOG Yearly Net Income VS EBIT VS OCF VS FCFNEOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M -800M -1B

1.2 Ratios

  • NEOG has a Return On Assets (-17.94%) which is comparable to the rest of the industry.
  • NEOG has a Return On Equity (-28.64%) which is in line with its industry peers.
Industry RankSector Rank
ROA -17.94%
ROE -28.64%
ROIC N/A
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
NEOG Yearly ROA, ROE, ROICNEOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40

1.3 Margins

  • The Gross Margin of NEOG (45.98%) is worse than 60.54% of its industry peers.
  • In the last couple of years the Gross Margin of NEOG has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for NEOG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
NEOG Yearly Profit, Operating, Gross MarginsNEOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

4

2. Health

2.1 Basic Checks

  • NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NEOG remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, NEOG has more shares outstanding
  • NEOG has a worse debt/assets ratio than last year.
NEOG Yearly Shares OutstandingNEOG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
NEOG Yearly Total Debt VS Total AssetsNEOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • Based on the Altman-Z score of 1.31, we must say that NEOG is in the distress zone and has some risk of bankruptcy.
  • NEOG has a Altman-Z score of 1.31. This is comparable to the rest of the industry: NEOG outperforms 55.68% of its industry peers.
  • NEOG has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
  • NEOG has a Debt to Equity ratio of 0.38. This is comparable to the rest of the industry: NEOG outperforms 48.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z 1.31
ROIC/WACCN/A
WACC10.21%
NEOG Yearly LT Debt VS Equity VS FCFNEOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 3.91 indicates that NEOG has no problem at all paying its short term obligations.
  • NEOG has a Current ratio of 3.91. This is in the better half of the industry: NEOG outperforms 66.49% of its industry peers.
  • A Quick Ratio of 2.80 indicates that NEOG has no problem at all paying its short term obligations.
  • NEOG has a better Quick ratio (2.80) than 63.78% of its industry peers.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 2.8
NEOG Yearly Current Assets VS Current LiabilitesNEOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

3

3. Growth

3.1 Past

  • NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.50%.
  • Measured over the past years, NEOG shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.20% on average per year.
  • The Revenue has decreased by -3.67% in the past year.
  • Measured over the past years, NEOG shows a quite strong growth in Revenue. The Revenue has been growing by 16.43% on average per year.
EPS 1Y (TTM)-27.5%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-9.09%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-2.84%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.29% on average over the next years.
  • NEOG is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.50% yearly.
EPS Next Y-9.33%
EPS Next 2Y1.38%
EPS Next 3Y9.52%
EPS Next 5Y7.29%
Revenue Next Year-4.55%
Revenue Next 2Y-1.49%
Revenue Next 3Y-0.67%
Revenue Next 5Y-0.5%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NEOG Yearly Revenue VS EstimatesNEOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
NEOG Yearly EPS VS EstimatesNEOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 0.4 0.6

2

4. Valuation

4.1 Price/Earnings Ratio

  • NEOG is valuated quite expensively with a Price/Earnings ratio of 39.07.
  • Compared to the rest of the industry, the Price/Earnings ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 71.35% of the companies listed in the same industry.
  • NEOG is valuated rather expensively when we compare the Price/Earnings ratio to 26.99, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 33.41 indicates a quite expensive valuation of NEOG.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 70.81% of the companies listed in the same industry.
  • NEOG is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 39.07
Fwd PE 33.41
NEOG Price Earnings VS Forward Price EarningsNEOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 68.11% of the companies in the same industry are more expensive than NEOG, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 34.38
NEOG Per share dataNEOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.38%
EPS Next 3Y9.52%

0

5. Dividend

5.1 Amount

  • No dividends for NEOG!.
Industry RankSector Rank
Dividend Yield 0%

NEOGEN CORP

NASDAQ:NEOG (2/20/2026, 8:00:01 PM)

After market: 11.36 +0.03 (+0.26%)

11.33

+0.35 (+3.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-08
Earnings (Next)04-07
Inst Owners111.94%
Inst Owner Change-10.99%
Ins Owners0.61%
Ins Owner Change27.83%
Market Cap2.46B
Revenue(TTM)880.32M
Net Income(TTM)-602.74M
Analysts78.18
Price Target11.22 (-0.97%)
Short Float %5.51%
Short Ratio3.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)87.17%
Min EPS beat(2)78.25%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)32.2%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)3
Avg EPS beat(8)11.3%
EPS beat(12)5
Avg EPS beat(12)119.18%
EPS beat(16)6
Avg EPS beat(16)37.27%
Revenue beat(2)2
Avg Revenue beat(2)3.22%
Min Revenue beat(2)0.46%
Max Revenue beat(2)5.99%
Revenue beat(4)2
Avg Revenue beat(4)0.6%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)5.99%
Revenue beat(8)3
Avg Revenue beat(8)0.18%
Revenue beat(12)4
Avg Revenue beat(12)-0.24%
Revenue beat(16)4
Avg Revenue beat(16)-0.78%
PT rev (1m)0%
PT rev (3m)44.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.69%
EPS NY rev (1m)22.22%
EPS NY rev (3m)22.22%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)3.31%
Valuation
Industry RankSector Rank
PE 39.07
Fwd PE 33.41
P/S 2.8
P/FCF N/A
P/OCF 37.23
P/B 1.17
P/tB N/A
EV/EBITDA 34.38
EPS(TTM)0.29
EY2.56%
EPS(NY)0.34
Fwd EY2.99%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)0.3
OCFY2.69%
SpS4.05
BVpS9.67
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.95
Profitability
Industry RankSector Rank
ROA -17.94%
ROE -28.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.98%
FCFM N/A
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score4
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA 8.98
Cap/Depr 71.99%
Cap/Sales 9.62%
Interest Coverage N/A
Cash Conversion 74.97%
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 2.8
Altman-Z 1.31
F-Score4
WACC10.21%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.5%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-9.09%
EPS Next Y-9.33%
EPS Next 2Y1.38%
EPS Next 3Y9.52%
EPS Next 5Y7.29%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-2.84%
Revenue Next Year-4.55%
Revenue Next 2Y-1.49%
Revenue Next 3Y-0.67%
Revenue Next 5Y-0.5%
EBIT growth 1Y-193.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year138.34%
EBIT Next 3Y34.61%
EBIT Next 5Y20.01%
FCF growth 1Y-209.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.22%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%

NEOGEN CORP / NEOG FAQ

What is the fundamental rating for NEOG stock?

ChartMill assigns a fundamental rating of 3 / 10 to NEOG.


What is the valuation status of NEOGEN CORP (NEOG) stock?

ChartMill assigns a valuation rating of 2 / 10 to NEOGEN CORP (NEOG). This can be considered as Overvalued.


How profitable is NEOGEN CORP (NEOG) stock?

NEOGEN CORP (NEOG) has a profitability rating of 2 / 10.


What is the financial health of NEOGEN CORP (NEOG) stock?

The financial health rating of NEOGEN CORP (NEOG) is 4 / 10.


What is the expected EPS growth for NEOGEN CORP (NEOG) stock?

The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -9.33% in the next year.